Abbott Laboratories will spend $110 million to buy a potential kidney treatment from the privately held Danish company Action Pharma, the company said Thursday.
The drug, labeled AP214, is in mid-stage clinical testing and is designed to prevent acute kidney injury in patients undergoing major cardiac surgery. The molecule targets systemic inflammation and cellular death caused by a lack of blood flow that can occur during surgery.
North Chicago-based Abbott said the deal will improve its pipeline of renal care drugs under development, which includes two potential chronic kidney disease treatments.
